IDO1 and neuroblastoma: Therefore, high‐risk 11q‐deleted NB patients may preferentially benefit from the combination of anti‐GD2 immunotherapy with immune checkpoint inhibitors (i.e., anti‐PD‐L1, anti‐CTLA‐4, IDO1 inhibitors, etc.)to disable immune escape.